Angiogenesis - PowerPoint PPT Presentation

angiogenesis l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Angiogenesis PowerPoint Presentation
Download Presentation
Angiogenesis

play fullscreen
1 / 8
Angiogenesis
1396 Views
Download Presentation
joanne
Download Presentation

Angiogenesis

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Sprouting angiogenesis involves multiple linked and sequential steps that include endothelial cell proliferation, migration, invasion, survival, and capillary tube formation; mediated by multiple angiogenic factors, the most important of which is VEGF. Ellis. Horizons in Cancer Therapeutics. 2004;5(2):4-10. Angiogenesis

  2. VEGF family members bind to specific VEGF membrane-bound tyrosine kinase receptors, eliciting the functions described in this slide. Ellis. Horizons in Cancer Therapeutics. 2004;5(2):4-10. VEGF Family and Receptors

  3. Anti–VEGFR-2 Antibody Reduces Tumor Interstitial Pressure Treatment with anti–VEGFR-2 antibody led to a rapid reduction in murine lung and glioma tumor interstitial pressures. From Tong et al. Cancer Res. 2004;64:3731-3736, with permission.Ellis. Horizons in Cancer Therapeutics. 2004;5(2):4-10.

  4. PTK787/ZK 222584 Reduces Liver Metastasis Ki PTK787/ZK 222584 reduced perfusion parameters (Ki) in nonprogressing patients with colorectal cancer liver metastasis. From Morgan et al. J Clin Oncol. 2003;21:3955-3964,with permission. Ellis. Horizons in Cancer Therapeutics. 2004;5(2):4-10.

  5. Modulating VEGF/VEGFR Signaling Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) signaling modulation approaches include targeting VEGF/VEGFR with antibodies, reducing VEGF expression with fusion proteins, using ribozymes to decrease receptor expression and activation, and reducing receptor activation and downstream signaling. TKI = tyrosine kinase inhibitors. Steward. Horizons in Cancer Therapeutics. 2004;5(2):11-21.

  6. PTK787/ZK 222584 (PTK/ZK) significantly inhibited human DU-145 prostate cancer xenografts in nude mice. Tumor growth resumed on cessation of treatment, demonstrating the cytostatic rather than cytotoxic effects of PTK/ZK. From Bold et al. Prous Sci Drugs Future. 2002;27:43-55, with permission. Steward. Horizons in Cancer Therapeutics. 2004;5(2):11-21. PTK787/ZK 222584 in Prostate Cancer Xenografts

  7. PTK787/ZK 222584 Reduces Liver Metastasis Perfusion Baseline (top) and day 2 (bottom; ~30h postdose) images show reduction in perfusion and permeability of liver metastasis (arrow) after bolus PTK787/ZK 222584. From Morgan et al.J Clin Oncol. 2003;21:3955–3964, with permission. Steward. Horizons in Cancer Therapeutics. 2004;5(2):11-21.

  8. PTK787/ZK 222584 Reduces Liver Metastasis Volume MRI images from a colorectal cancer patient show a reduction in liver metastasis(highlighted by shaded areas in lower panels) after PTK787/ZK 222584. Steward. Horizons in Cancer Therapeutics. 2004;5(2):11-21.